FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate

- Lehman, Margot, Hayden, Amy J., Martin, Jarad M., Christie, David, Kneebone, Andrew B., Sidhom, Mark, Skala, Marketa, Tai, Keen-Hun

FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part II post-radical prostatectomy

- Lehman, Margot, Sidhom, Mark, Kneebone, Andrew B., Hayden, Amy J., Martin, Jarad M., Christie, David, Skala, Marketa, Tai, Keen-Hun

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

- Capp, Anne, Inostroza-Ponta, Mario, Atkinson, Chris, North, John, Poulsen, Michael, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Steigler, Allison, Denham, James W., Bill, Dana, Moscato, Pablo, Lai, Chi, Christie, David, Lamb, David, Turner, Sandra, Joseph, David, Matthews, John

Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial

- Sridharan, Swetha, Steigler, Allison, Attia, John, Holliday, Elizabeth G., Denham, James W., Spry, Nigel A., Joseph, David, Lamb, David S., Matthews, John H., Atkinson, Chris, Tai, Keen-Hun, Duchesne, Gillian, Christie, David

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

- Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial

- Steigler, Allison, Denham, James W., Tai, Keen-Hun, Wynne, Chris, Lamb, David S., Spry, Nigel A., Joseph, David, Matthews, John, Atkinson, Chris, Turner, Sandra, North, John, Christie, David

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David